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Background: Patients who require a switch in their antidepressant therapy may have different clinical profiles and
treatment needs compared with patients initiating or maintaining a first-line antidepressant therapy.
Methods: The Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder
(MDD) (PERFORM) study was a 2-year observational cohort study in outpatients with MDD in five European countries.
Enrolled patients were either initiating or undergoing the first switch to an antidepressant monotherapy. Baseline data
on patients’ clinical status, functioning, productivity, quality of life and medical-resource use were compared in a cross-
sectional baseline analysis.
Results: A total of 1402 patients were enrolled, of whom 1159 (82.7%) provided analysable baseline data. The majority
(78.7%) of the analysable population were initiating antidepressant treatment and most (83.6%) were enrolled
and followed up by general practitioners. Compared with patients initiating antidepressants, those switching
antidepressants (21.3%) tended to have more severe depressive symptoms, greater anxiety, worse health-related quality
of life, greater functional impairment, greater medical-resource use and had a different medical history. Limitations
included an over-representation of switches due to lack of efficacy among patients who were switching treatment, as
patients were selected based on presence of depressive symptoms.
Conclusions: Patients with MDD who are switching treatment for the first time have a different profile and different
depression-associated health needs compared with those initiating treatment. Therapeutic management should therefore
be adapted for patients who switch.
Trial registration: ClinicalTrials.gov NCT01427439; Retrospectively registered 26 August 2011.
Keywords: Depression, Drug switching, Observational study, Baseline surveyBackground
Pharmacological therapies are commonly used in the
management of patients with depression; however, a sig-
nificant proportion of patients do not respond to an ad-
equate trial of the first antidepressant prescribed in a
depressive episode [1–3]. The Sequenced Treatment Al-
ternatives to Relieve Depression (STAR*D) trial reported
that up to 37% of patients initiating antidepressant* Correspondence: LEEM@lundbeck.com
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first-line treatment [2, 4]. Change of treatment is thus a
frequent therapeutic action in patients with depression
who do not respond to their initial treatment. Treatment
guidelines recommend a range of pharmacotherapeutic
approaches for patients who need a treatment change
from their first-line treatment, including treatment switch
(changing to a different antidepressant), combination ther-
apy (adding a second antidepressant) and augmentation
(adding an agent that is not generally considered an anti-
depressant, e.g. an antipsychotic) [5–8]. Switching therapyle is distributed under the terms of the Creative Commons Attribution 4.0
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equate response and/or tolerability problems, whereas
combination and augmentation strategies would be used
for patients who had experienced a partial response to the
initial therapy but had residual symptoms and had not ex-
perienced tolerability problems [9]. Several studies have
found that switching is a common choice in clinical prac-
tice for patients requiring second-line treatment, including
those with an inadequate response to first-line antidepres-
sant therapy [10–13]. Clinical evidence supports switching
antidepressants in such patients [14, 15].
In considering a switch from first-line treatment,
guidelines recommend taking into account whether the
patient has experienced adverse effects and patient pref-
erence [5, 8]. However, some studies have shown that, in
clinical practice, patients who switch antidepressants
may have a very different clinical profile compared with
those who do not switch treatment. An observational
study based on data from the General Practice Research
Database (GPRD; now known as the Clinical Practice
Research Datalink) in the UK found that patients who
switched antidepressants tended to have a more severe
psychiatric profile compared with those who maintained
their initial therapy [12]. In addition, differences in the
degree of resolution for symptoms of occupational im-
pairment have been noted between patients responding
to first-line treatment and those responding to second-
line treatment [16]. Such findings suggest that patients
who require a switch in their antidepressant therapy
may benefit from a more detailed clinical assessment of
their illness and a specific management approach, dis-
tinct from that taken with patients who are initiating or
maintaining a first-line antidepressant therapy.
The Prospective Epidemiological Research on Func-
tioning Outcomes Related to Major depressive disorder
(MDD) (PERFORM) study was designed to better under-
stand the course of a depressive episode and its impact
on patient functioning over a 2-year period in patients
with MDD in clinical practice in five European coun-
tries. The study recruited patients with a diagnosis of
MDD who were either initiating antidepressant mono-
therapy or who were switching antidepressant mono-
therapy for the first time. The aim of the cross-sectional
baseline analyses presented in this paper was to describe
the characteristics of patients who were initiating or
switching antidepressant monotherapy when entering
the PERFORM study and to compare their depression-
related clinical profile, daily functioning, health-related
quality of life and resource use.
Methods
Study design and patients
The PERFORM study is a 2-year observational cohort
study in outpatients with MDD enrolled by either aprimary care physician or a psychiatrist at 194 sites in five
European countries (France, Germany, Spain, Sweden and
the UK). In each country the study sites were selected to
reflect the national proportions of these clinicians treating
patients with depression. At enrolment, eligible patients
were aged 18–65 years, had a current diagnosis of MDD
according to the Diagnostic and Statistical Manual of
Mental Disorders IV Text Revision (DSM-IV-TR), and
were either initiating antidepressant monotherapy or were
undergoing their first switch of antidepressant. Patients
were excluded if they had schizophrenia or other psych-
otic disorders; bipolar disorder; substance dependence; de-
mentia or other neurodegenerative disease significantly
affecting cognitive functioning; or a mood disorder due to
a general medical condition or substances. Patients receiv-
ing a combination of different antidepressant treatments
at the time of the initial consultation were also excluded.
The physician’s choice of the drug used to treat each
patient was based on clinical judgement alone and was
not influenced by the decision to enter the study. All pa-
tients enrolled in the study provided written informed
consent. The necessary ethical approvals were obtained
for each study site before study initiation. The study
was registered at ClinicalTrials.gov: NCT01427439 on
26 August 2011.
Baseline characteristics
Patient characteristics recorded at baseline included
demographic information; the characteristics of the
current episode of depression and – for patients switch-
ing antidepressants – the main reason for switching, ac-
cording to the physician; history of depression; and the
presence of mental health disorders other than depres-
sion, and of any functional syndromes.
Clinical profile at baseline was assessed by all patients
using the 9-item Patient Health Questionnaire (PHQ-9)
[17] and by all participating investigators using the Clin-
ical Global Impressions–Severity of illness scale (CGI-S)
[18]. The Montgomery–Åsberg Depression Rating Scale
(MADRS) [19] was also administered when recruitment
was conducted in the specialized sector and patients
were evaluated by psychiatrists. The PHQ-9 scores were
used to categorize the severity of symptoms as “minimal”
(score 0–4), “mild” (score 5–9), “moderate” (score 10–
14), “moderately severe” (score 15–19) or “severe” (score
20–27) for analysis. The CGI-S responses were analysed
by the category assigned by the physician on a 7-point
scale ranging from 1 = not ill, to 7 = extremely ill. The
MADRS responses were analysed by total score.
Daily functioning and quality of life were assessed
using self-administered instruments. Functioning was
evaluated using the Sheehan Disability Scale (SDS) [20]
including three dimensions (work, social and family
functioning). The “activity impairment” dimension of the
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(WPAI) was also applied in order to evaluate functioning
[21]. The other dimensions of the WPAI are not presented
as they aim to measure productivity and are relevant only
to the subpopulation in employment. The Arizona Sexual
Experience Scale (ASEX; five items, each scored from 1 to
6) [22] was used to assess sexual functioning. Patients
were categorized as having sexual dysfunction if their total
ASEX score was ≥19 or their score was ≥5 for one item
or ≥ 4 for at least three items. Patient-reported outcomes
were also used to assess health-related quality of life using
the physical and mental health dimensions of the Medical
Outcomes Study Short-Form (12-item) Health Survey
(SF-12) [23] and the EuroQol 5-Dimensions questionnaire
(EQ-5D; in UK patients only) [24]. Utility scores were de-
rived from the EQ-5D scales by applying UK tariffs [25].
Resource use during the 12 weeks before baseline was
assessed by physician reporting of physician visits, hospi-
talizations and periods of sick leave. Resource-use data
were reported for patients who had experienced a de-
pressive episode of at least 8 weeks’ duration as: per cent
of patients reporting at least one visit (physician or other
healthcare professional) or 1 day of hospitalization or
sick leave over the recall period; number of visits (phys-
ician or other healthcare professional) or days of
hospitalization or sick leave for patients with at least one
visit or day of the corresponding resource item; and
overall number of visits (physician or other healthcare
professional) or days of hospitalization or sick leave. The
restriction of this analysis to patients with a minimum
depressive-episode duration of 8 weeks was applied to
allow an appropriate comparison between the two treat-
ment groups, given the between-group difference in dur-
ation of the current depressive episode.
Data analysis
Patients included in the analysable dataset were those who
met the study selection criteria and completed a baseline
assessment form as well as at least one post-baseline as-
sessment or outcome questionnaire. Summary statistics
(mean, standard deviation, median, minimum and max-
imum) were calculated for continuous variables, and num-
bers and percentages were calculated for categorical
variables. Analyses were performed for both groups of
patients: those switching and those initiating treatment.
Differences between these groups were investigated using
either Student’s t test for quantitative variables or chi-
squared test (or Fisher’s exact test where appropriate) for
qualitative variables. All analyses were univariate as the
aim was to describe the characteristics of the study popu-
lations rather than to explain or identify any associations.
Statistical significance was assumed at p < 0.05. Statistical
analyses were performed using SAS® statistical software,
Version 9.2 (SAS Institute, Cary, NC, USA).Results
Subjects
A total of 1895 patients were screened, 1402 of whom
were enrolled in the study. The first patient was
screened on 25 February 2011 and the last patient com-
pleted the study on 19 February 2015. The most fre-
quent reason for non-enrolment of screened patients
(n = 493) was patient’s decision (n = 203; 41.2%). Of
those who were enrolled, 1159 (82.7%) provided analys-
able data. Patients who were enrolled but not included
in the analysable population (n = 243) were excluded be-
cause they violated at least one of the inclusion and/or
exclusion criteria at baseline (n = 167) or they had not
completed a post-baseline case report form or at least
one post-baseline questionnaire in the predefined time-
frame (n = 101, including 76 who met the inclusion cri-
teria at baseline). The majority of patients were enrolled
and followed up by general practitioners (n = 969;
83.6%). Overall the analysable population had a mean
age of approximately 44 years, and the majority (n = 848;
73.2%) were female (Table 1). Included patients were
from the UK (n = 341; 29.4%), France (n = 339; 29.2%),
Spain (n = 270; 23.3%), Germany (n = 164; 14.2%) and
Sweden (n = 45; 3.9%).
At baseline 910 (78.7%) patients were initiating anti-
depressant treatment and 247 (21.3%) were switching
antidepressant for the first time; the treatment status of
two patients was unknown. The main causes of switch-
ing (recorded for 216 patients) were lack of efficacy
(n = 167; 77.3%), adverse events (n = 20; 9.3%), patient’s
decision (n = 15; 6.9%) and lack of compliance (n = 7;
3.2%). Compared with patients who were initiating antide-
pressants, approximately twice as many patients in the
analysable population who were switching antidepressants
were being treated by psychiatrists at the time of enrol-
ment (n = 124 vs 66, respectively; P < 0.001; Table 2).
There were statistically significant demographic differ-
ences between the two patient groups: compared with
patients who were initiating treatment, those who were
switching were significantly older (P = 0.012) and more
likely to be widowed or divorced/separated (Table 1). Pa-
tients who were initiating antidepressant treatment were
more likely to be educated to university degree level and
were more likely to be in paid employment or self-
employed compared with patients who were switching
antidepressant treatment (Table 1).
Clinical profile
With regard to their current episode of depression, the
duration of the episode – classified in time categories –
differed significantly (P < 0.001) between the two patient
groups. Greater proportions of patients who were
switching antidepressants than those initiating treatment
had been experiencing the current episode of depression
Table 1 Patient characteristics at baseline
Characteristic Switching (n = 247)a Initiating (n = 910)a P-value: switching vs initiating Total (n = 1159)b
Age, mean ± SD (years) 46.0 ± 11.7 43.8 ± 12.0 0.012 44.3 ± 12.0
Female (%) 76.1 72.5 0.259 73.2
Marital status (%) 0.021
Single 20.6 21.9 21.6
Married/couple 54.7 59.6 58.5
Divorced/separated 18.6 16.2 16.7
Widowed 6.1 2.4 3.2
Education (%) < 0.001
No degree or diploma 8.1 3.5 4.5
Elementary school 32.8 22.1 24.4
High school 31.6 38.4 36.9
Non-university degree 13.0 14.3 14.0
University degree 14.6 21.8 20.2
Work status (%)
Paid employment or self-employed 59.5 68.8 0.006 66.8
Unemployed 20.2 17.1 0.259 17.8
Abbreviation: SD standard deviation
P-values in bold indicate statistically significant differences
aNumber of patients included in the between-group comparison; information regarding whether the patient was initiating or switching treatment was missing for
two patients
bTotal number of patients providing data
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higher proportion of patients who were switching treat-
ment were experiencing symptoms of anxiety (P < 0.001);
among patients with anxiety, those who were switching
were significantly more likely to be treated with anxiolytics
(P = 0.004).
Severity of illness, as rated by the patient using the
PHQ-9, indicated little clinical difference between the
treatment groups. Although the between-group differ-
ence in mean scores reached statistical significance (P =
0.014), the mean score was only marginally higher for
patients switching antidepressants versus those initiating
treatment (Table 2). Conversely, the difference in distri-
bution by category of severity did not reach statistical
significance (P = 0.084), despite a greater proportion of
patients who switched treatment ranking their illness as
severe (PHQ-9 score 20–27) compared with those initi-
ating antidepressant treatment (Fig. 1).
The severity of the current depressive episode, as mea-
sured by the mean physician-assigned CGI-S score, was
significantly higher in patients who were switching antide-
pressants compared with those initiating the treatment
(P < 0.001) (Table 2). The profile of disease severity dif-
fered significantly in the two populations (P < 0.001), with
a greater proportion of patients in the switching group
rated as markedly, severely or extremely ill (48.4% versus
36.2% in the initiating group) (Fig. 2).Compared with patients initiating antidepressant mono-
therapy, significantly greater proportions of patients
switching antidepressants had experienced a previous epi-
sode of depression at any time (P < 0.001; Table 2).
No significant differences were seen with regard to the
presence of comorbid mental disorders, but differences were
noted for comorbid physical disorders: significantly higher
proportions of patients who were switching had a diagnosis
of a chronic pain (P < 0.001) or fibromyalgia (P < 0.001)
compared with those initiating treatment (Table 2).
Functioning and health-related quality of life
With regard to functioning as assessed by the SDS, the
mean total SDS score was significantly higher – indicating
greater functional impairment – in patients who were
switching compared with those initiating antidepressants
(P = 0.004) (Table 2). Furthermore, the individual SDS do-
main scores were also significantly higher in patients who
were switching (each P < 0.05) (Table 2). The WPAI di-
mension of overall activity impairment showed a signifi-
cant between-group difference, with a significantly higher
mean score, i.e. worse impairment, in the group switching
than in the group initiating antidepressants (P = 0.002;
Table 2). The mean total ASEX sexual-function score was
statistically significantly higher in the group switching
than in the group initiating antidepressants (P = 0.031), al-
though the numerical difference was small (Table 2).








Characteristics of current depressive episode
Treating physician (% of patient group) (247) (910) < 0.001 (1159)
General practitioner 73.3 86.4 83.6
Psychiatrist 26.7 13.6 16.4
Duration of episode (%)c (247) (910) < 0.001 (1157)
< 1 week 0.4 1.9 1.6
1–2 weeks 2.8 6.7 5.9
2–4 weeks 14.6 23.2 21.3
4–8 weeks 17.4 20.4 19.8
> 8 weeks 64.8 47.8 51.4
Significant symptoms of anxiety (%)d 74.5 (247) 59.3 (910) < 0.001 62.6 (1158)
Symptoms treated with anxiolytics (%) 53.1 (130) 38.6 (376) 0.004 42.2 (507)
Questionnaire scores, mean ± SD
PHQ-9 18.4 ± 5.3 (198) 17.4 ± 5.3 (740) 0.014 17.6 ± 5.3 (940)
CGI-S 4.4 ± 1.0 (246) 4.1 ± 1.0 (908) < 0.001 4.2 ± 1.0 (1155)
MADRSe 32.5 ± 7.1 (66) 32.9 ± 7.2 (124) 0.724 32.7 ± 7.1 (190)
SDS
Total score 20.6 ± 6.6 (147) 18.9 ± 6.7 (601) 0.004 19.2 ± 6.8 (750)
Work/school disruption 6.7 ± 2.7 (150) 6.1 ± 2.8 (614) 0.020 6.3 ± 2.8 (766)
Social life/leisure activities’ disruption 7.0 ± 2.4 (179) 6.4 ± 2.5 (704) 0.003 6.6 ± 2.5 (885)
Family life/home duties’ disruption 7.0 ± 2.4 (179) 6.4 ± 2.5 (701) 0.001 6.5 ± 2.5 (882)
WPAIf 66.0 ± 23.5 (194) 59.9 ± 24.9 (740) 0.002 61.1 ± 24.8 (936)
ASEX
Total score 22.2 ± 5.8 (169) 21.2 ± 5.7 (623) 0.031 21.4 ± 5.7 (793)
Sexual dysfunction (%) 84.6 (188) 80.3 (695) 0.182 81.1 (884)
SF-12 (190) (720) (912)
PCS 40.6 ± 11.4 46.4 ± 12.0 < 0.001 45.2 ± 12.1
MCS 26.8 ± 9.0 26.4 ± 9.2 0.598 26.5 ± 9.2
EQ-5D utility scoreg 0.5 ± 0.3 (48) 0.6 ± 0.3 (227) 0.044 0.5 ± 0.3 (276)
Other current illnesses
Mental-health disorders other than depression (%) (247) (910) (1159)
Alcohol abuse or dependence 1.6 3.0 0.245 2.7
Other abuse disorders 1.2 1.3 1.000 1.3
Somatoform disorders 10.5 7.0 0.069 7.9
Eating disorders (anorexia, bulimia) 10.5 7.5 0.119 8.1
Other 0.0 0.8 0.357 0.6
Functional syndromes (%) (247) (910) (1159)
Chronic pain 23.9 14.7 < 0.001 16.7
Chronic fatigue 17.0 15.9 0.685 16.1
Fibromyalgia 13.0 5.2 < 0.001 6.8
Premenstrual syndrome 4.9 3.1 0.174 3.5
Sleep disorders 29.1 27.9 0.701 28.2
Other 2.4 2.9 0.716 2.8
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History of depression (%)
Previous episode 72.0 (246) 52.4 (910) < 0.001 56.6 (1157)
Episode within previous 12 months if previous episode 33.9 (177) 22.4 (477) 0.003 25.5 (655)
Antidepressant treatment if previous episode 91.0 (177) 77.1 (476) < 0.001 80.9 (654)
Previous hospitalization for depression 15.3 (177) 6.5 (477) < 0.001 8.9 (655)
Remission of previous episode 72.3 (177) 87.2 (477) < 0.001 83.2 (655)
Previous suicide attempt 18.1 (177) 11.3 (477) 0.023 13.1 (655)
Abbreviations: ASEX Arizona Sexual Experience Scale, CGI-S Clinical Global Improvement Severity scale, EQ-5D EuroQol 5-Dimensions questionnaire,
MADRS Montgomery–Åsberg Depression Rating Scale, MCS mental component summary, PCS physical component summary, PHQ-9 9-item Patient Health
Questionnaire, SD standard deviation, SDS Sheehan Disability Scale, SF-12 Medical Outcomes Study Short-Form (12-item) Health Survey, WPAIWork Productivity and
Activity Impairment questionnaire
P-values in bold indicate statistically significant differences
aNumber of patients included in the between-group comparison; information regarding whether the patient was initiating or switching treatment was missing for
two patients
bTotal number of patients providing data
cPhysicians’ response
dThe percentages refer to patients “probably” or “definitely” presenting clinically significant symptoms of anxiety according to physician; the P-value indicates the
between-group comparison taking into account all five categories (“definitely”, “probably”, “probably not”, “definitely not” and “don’t know”)
eAssessment used by psychiatrists only
fActivity impairment due to problem
gUK sample population only
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score was significantly lower (indicating worse physical
functioning) in the switching compared with the initiat-
ing group (P < 0.001); however the mean mental compo-
nent summary (MCS) score did not differ between
groups (Table 2).
Resource use
Resource use within the 12 weeks before the baseline
visit by patients with a depressive episode of greater than
8 weeks’ duration is summarized in Table 3. Compared
with patients who initiated antidepressant medication, a
statistically significantly greater proportion of patientsFig. 1 Distribution of PHQ-9 score categories at baseline, by treatment
status. aThe between-group comparison of the categorical data was
conducted using a chi-squared test. Abbreviations: AD antidepressant,
PHQ-9, 9-item Patient Health Questionnairewho were switching antidepressants made at least one
visit to any physician in the previous 12 weeks (88.0% vs
96.2%; P = 0.003). Patients who were switching antide-
pressants had more physician visits than patients initiat-
ing treatment in the same period (Table 3).
In terms of the type of physician visited, patients who
were switching were also significantly more likely than
those initiating treatment to have visited a psychiatrist
(P = 0.001) or psychotherapist/counselling (P = 0.047) in
the previous 12 weeks. A significantly greater proportion
of patients switching antidepressants than those initiat-
ing treatment had taken at least one period of sick leave
in the previous 12 weeks (P = 0.033).Fig. 2 Distribution of CGI-S score categories at baseline by treatment
status. aThe between-group comparison of the categorical data was
conducted using Fisher’s exact test. Abbreviations: AD antidepressant,
CGI-S Clinical Global Improvement Severity scale
Table 3 Resource use for patients with a depressive episode of more than 8 weeks’ durationa
Resource use in the
past 12 weeks




No. of physician visits (157) (432) < 0.001 (589)
0 3.8 12.0 9.8
1 10.8 22.5 19.4
2 11.5 17.6 16.0
3 17.2 13.2 14.3
≥ 4 56.7 34.5 40.4
Unknown 0 0.2 0.2
General practitioner (any cause)d 91.2 (160) 82.8 (435) 0.010 85.0 (595)
Psychiatristd 27.5 (160) 15.9 (435) 0.001 19.0 (595)
Psychotherapist/counsellingd 19.4 (160) 12.9 (435) 0.047 14.6 (595)
Other specialistd 26.2 (160) 19.1 (435) 0.057 21.0 (595)
Hospitalization 3.8 (160) 2.1 (435) 0.248 2.5 (595)
Sick leave 90.5 (63) 78.0 (141) 0.033 81.9 (204)
P-values in bold indicate statistically significant differences
an = 595 patients in total: n = 160 switching and n = 435 initiating antidepressant therapy
bNumber of patients included in between-group comparison
cTotal number of patients providing data
dPatients (n = 8–20 in total for each resource) for whom the information was reported as ‘unknown’ by the physician were included in the analysis as having used
the resource
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The objective of this paper was to describe and compare
the baseline characteristics of patients with MDD who
initiated versus switched antidepressant treatment for
the first time at inclusion in the PERFORM study. Over-
all, the baseline characteristics indicate significant differ-
ences between patients who are initiating and those who
are switching antidepressants (i.e. undergoing first- and
second-line monotherapy, respectively) in the course of
a depressive episode. Compared with patients initiating
antidepressants, those switching antidepressants tended
to have more severe depressive symptoms, greater anx-
iety, worse health-related quality of life and greater func-
tional impairment; be more likely to experience chronic
pain and fibromyalgia; have a different socioeconomic
and medical-history background; and use more health-
care resources.
Switching antidepressants is likely to be a common ap-
proach in clinical practice [10–13]. This is particularly
the case in patients who fail to achieve an adequate re-
sponse with an initial antidepressant [10, 13]. For ex-
ample, in a retrospective cohort study of medical
records of patients with depression in Spain, 43% of
those with an inadequate response to first-line anti-
depressant treatment were switched to another anti-
depressant [13]. A high proportion of patients in clinical
trials and clinical practice do not respond adequately to
first-line treatment [2, 4, 26–32]. Switching antidepres-
sants has been demonstrated to be effective in a number
of clinical studies, with remission rates of up to 42%achieved in patients who previously failed to achieve re-
mission [14, 15, 33]. While current guidelines recom-
mend switching antidepressants if a patient who has
adhered to the prescribed treatment regimen fails to
achieve a satisfactory response to initial antidepressant
treatment [5, 8], they do not generally recommend a
specific assessment of severity, functioning or other as-
pects of the patient’s depressive episode when consider-
ing switching to second-line therapy.
The observation in the current study that the patients
switching antidepressants were reporting more severe de-
pressive symptoms than those initiating antidepressants is of
particular note, given that the patients switching treatment
had been receiving antidepressant treatment for some time.
The patients who switched treatment may have been even
more severely depressed when they initiated treatment. Al-
though the mean between-group differences in depression
severity scores were not large, they were consistent across
patient (PHQ-9) and physician (CGI-S) reports.
Approximately 77% of patients who switched in the
present study did so because of lack of efficacy. How-
ever, in other studies lower proportions of patients have
cited this as the reason: a previous longitudinal natural-
istic study found that 41% of patients with depression
who switched within 4 weeks of initiating treatment said
it was due lack of efficacy [34]. The relatively high pro-
portion noted in the current study may in part be due to
selection bias as discussed below.
Differences in the profile of the current depressive epi-
sode and in the history of psychiatric illness have
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second-line treatment and those who maintain first-line
treatment [12]. In a study using historical cohort data
from the UK’s GPRD, patients who switched antidepres-
sant had more severe depression, were more likely to
have concomitant anxiety disorders and were more likely
to have experienced a previous episode of depression
than those maintaining treatment [12]. The present
study augments such findings by providing a more de-
tailed clinical profile of switching and non-switching
populations.
The results of the present analysis also suggest that pa-
tients who fail to respond adequately to first-line treat-
ment may experience more severe functional
impairment. In a cohort study Trivedi and colleagues
[16] found that although patients who responded to
first-line antidepressant treatment experienced improve-
ments in work productivity in parallel with reductions in
the severity of depressive symptoms, patients receiving
second-line treatment (i.e. those who switched or re-
ceived augmented treatment) did not experience such
improvements when they responded to treatment.
Compared with maintaining treatment, switching has
also been found to be associated with worse health-
related quality-of-life outcomes in a longitudinal study
of inpatients with MDD [35]. In the present study, the
mean SF-12 PCS score in the group switching antide-
pressants was considerably lower than might be ex-
pected in the general population [23, 36, 37], which may
also reflect the frequency of chronic pain and fibromyal-
gia in the study group. As would be expected, the mean
MCS scores were far lower than in the general popula-
tion (attributed a score of 50 ± 10.0 in a US general
population and 48.9 ± 9.2 in a Greek general population)
[23, 36, 37]. The mean MCS scores were similar in the
two patient groups in the current study. This is surprising
given the overall more severe depressive clinical profile in
the group switching antidepressants; however, this may re-
flect the improved sensitivity expected from a disease-
specific (PHQ-9) versus a generic instrument (SF-12).
In addition to factors such as those discussed above, there
are a multitude of other aspects of a patient’s life that influ-
ence their recovery from MDD, including life events and
personal circumstances. In the present study patients who
switched medication had a longer duration of illness, were
older, were more likely to be widowed or divorced, had
lower levels of educational achievement and were more
likely to be unemployed than patients initiating treatment.
While it is possible to speculate on the role of such factors
in patients’ response to treatment and recovery from MDD,
their contribution is difficult to gauge. Social disadvantage,
greater depression severity and anxiety have previously been
linked to reduced likelihood of achieving remission after
switching to second-line therapy in patients with MDD [38].Previous studies have demonstrated increased health-
care resource use by patients who switch therapy com-
pared with those who maintain their initial antidepressant
therapy [13, 39, 40]. For example, using data from a US
medical and pharmacy claims database, Schultz and Joish
[39] found that patients with MDD who switched therapy
incurred statistically significantly more depression-related
ambulatory, emergency-room and inpatient visits than
those who maintained their antidepressant therapy, lead-
ing to almost double the depression-related costs. The
greater resource use observed in patients who switch
would be anticipated, given their requirement for treat-
ment before switching.
Depression-associated functional impairment and re-
ductions in health-related quality of life have previously
been shown to be linked to the severity of the illness
[41, 42]. Some functional comorbidities, such as chronic
pain and fibromyalgia – which were significantly more
prevalent in the group switching antidepressants in the
present study – may influence health-related quality of life
independently of depressive symptoms and may contrib-
ute to greater severity of depression and functional im-
pairment [43–46]. Indeed, there is evidence of complex
interrelationships between depression and pain [47, 48].
The greater prevalence of anxiety in the group switching
antidepressants may also contribute to the greater severity
of depression seen in this group [49].
As in other therapeutic areas, with greater understand-
ing of the underlying pathophysiology of depression and
of the mechanisms of action of antidepressants, there is
the potential for personalized treatment, such that pa-
tients with particular depressive symptoms or features
may be prescribed specific pharmacotherapies [50].
Careful consideration of the patient’s full profile with the
aim of optimizing antidepressant treatment as early as
possible is warranted in light of observations that the
risk of treatment failure increases with the number of
lines of treatment required [2].
Strengths and limitations
The strengths of this study include the large sample size
and its international scope. In addition, this is one of the
first studies in which the collected baseline data com-
prise such a wealth of naturalistic information, including
detailed individual medical histories and both physician-
and patient-reported information on the current depres-
sive episode, as well as functional, quality-of-life and
resource-use data. The study population had the expected
demographic characteristics of patients with depression:
as previously reported in other observational studies, the
majority of patients with depression were women, and the
mean age of the population was approximately 45 years
[11, 51, 52]. Although the categorization of depression se-
verity using patient-reported outcome in the majority of
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frequently used in clinical trials) may be perceived as a
limitation of the study, this approach is increasingly recog-
nised as appropriate and may be considered a study
strength. Greater focus on patient-reported outcomes re-
flects the general move towards increased patient involve-
ment in treatment decisions, and awareness of the
limitations of the more ‘traditional’ clinical symptom-based
measures in assessing recovery from mental illness in a
way that is meaningful to patients [53–56]. In PERFORM a
validated questionnaire, based on DSM-IV diagnostic cri-
teria (PHQ-9) [17] was used to evaluate patient-reported
depression, and the severity levels revealed by physician as-
sessment using the CGI-S support the findings of the
patient-reported assessment that patients switching antide-
pressants had more severe depression.
We acknowledge a number of study limitations. Pa-
tients were selected on the basis of having symptoms of
depression, resulting in an over-representation in the
switching population of patients switching treatment
due to lack of efficacy (i.e. inadequate response to the
previous antidepressant) compared with other reasons.
The difference in depression severity between the two
study populations may therefore be greater than would
be seen in clinical practice; however, as drug-related ad-
verse effects (the next most common reason for switch-
ing) may affect functioning and quality of life to a
similar degree as a lack of efficacy, the potential bias to-
wards selecting patients with more severe depression in
the switching group may not have an effect on the find-
ings. The study comprised outpatients only, potentially
excluding some of the most severely affected patients.
These criteria may have led to the study population of
patients switching treatment having less severe depres-
sion than would be encountered in patients switching
treatment in clinical practice, however, in Europe the
vast majority of patients with MDD are treated in the
outpatient setting [1, 57]. The study also excluded patients
treated with combination or augmentation therapies.
However, guidelines currently applied in Europe recom-
mend initiating treatment with antidepressant monother-
apy, with a switch to a different monotherapy in the event
that an inadequate response is achieved with the initial
therapy [8]. It would therefore be anticipated that in clin-
ical practice few patients would receive a combination of
antidepressants or antidepressant therapy augmented with
another agent as either first- or second-line therapy. Be-
cause of these criteria, the outcomes may be more applic-
able to patients in the early rather than later period of
their depressive episode. A degree of recall bias may also
have occurred, which would have resulted in more exten-
sive retrospective reporting of medical issues and resource
use by the patients switching treatment. However, such
patients would genuinely have experienced more clinicalencounters as they had been treated for depression in the
preceding weeks; as the recall period was restricted to
12 weeks, the potential for recall bias is low. Analyses of
the MADRS and EQ-5D data were based on small sample
numbers as these tools were only used in specific settings.
This limits the statistical power of these analyses to detect
between-group differences. However, the reasonably good
response rate for other assessments of depression severity
and quality of life – despite the fact that completion of the
self-administered instruments was on an entirely volun-
tary basis – permitted reliable comparisons for these
characteristics.
Conclusions
In conclusion, the results of this analysis suggest that pa-
tients with depression who are switching treatment have
different profiles and depression-associated health needs
and should be managed differently from patients who are
initiating treatment. In such cases the physician should
consider the severity of depression and other aspects of
the patient’s illness, such as daily functioning and anxiety,
in order to select the optimal second-line treatment.
Additional files
Additional file 1: List of participating ethics committees. Details of all
participating local ethics committees. (DOCX 18 kb)
Abbreviations
ASEX: Arizona Sexual Experience Scale; CGI-S: Clinical Global Impressions–Severity
of illness scale; DSM-IV-TR: Diagnostic and Statistical Manual of Mental
Disorders IV Text Revision; EQ-5D: EuroQol 5-Dimensions questionnaire;
GPRD: General Practice Research Database; MADRS: Montgomery–Åsberg
Depression Rating Scale; MCS: Mental component summary; MDD: Major
depressive disorder; PCS: Physical component summary; PERFORM: Prospective
Epidemiological Research on Functioning Outcomes Related to Major depressive
disorder; PHQ-9: 9-item Patient Health Questionnaire; SDS: Sheehan Disability Scale;
SF-12: Medical Outcomes Study Short-Form (12-item) Health Survey;
STAR*D: Sequenced Treatment Alternatives to Relieve Depression; WPAI: Work
Productivity and Activity Impairment questionnaire
Acknowledgements
The authors thank Julien Chollet (Lundbeck) for his scientific and operational
contribution to the study and MAPI Registrat for the logistical management
of the study. The authors would also like to express their gratitude to all the
physicians and patients who kindly provided data for the study.
Editorial support in the development of the paper was provided by Dr. Julie
Ponting of Anthemis Consulting Ltd, funded by Lundbeck SAS.
Funding
This study was funded by Lundbeck SAS. Lundbeck personnel were involved
in the study design; in the collection and interpretation of data; in the writing
of the report; and in the decision to submit the article for publication.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
JMH, BJ, MK, DS and BR designed the study. HC conducted the analyses. All
authors interpreted the results, contributed to the development of the article
and approved the final article.
Haro et al. BMC Psychiatry  (2018) 18:80 Page 10 of 11Ethics approval and consent to participate
All patients enrolled in the study provided written informed consent. Ethical
approvals were obtained for each study site before study initiation. Further
details of local ethics committees are given in Additional file 1.
France: French health authority (ANSM, previously called AFSSAPS), advisory
committee on information processing in material research in the field of health
(CCTIRS), French data protection agency (CNIL), French National Medical Council
(CNOM), Ethics Committee (CPP Ile de France II); 102 physicians/sites included.
Germany: Munich Ethics Committee and local ethics committees;
47 physicians/sites included.
Spain: Agencia Española del Medicamento y Productos Sanitarios (AEMPS),
Comités Eticos de Investigaciones Clinicas (CEIC) of nine regions,
Comunidades Autónomas (CCAA) of 12 regions; 46 physicians/sites included.
Sweden: Uméå Ethics Committee; 22 physicians/sites included.
UK: Medical Research and Ethics Committee (MREC), National Institute for




JMH has received honoraria for participating in advisory boards for Eli Lilly
and Co, Roche, Lundbeck and Otsuka. F-XL was employed by Lundbeck SAS
at the time the study was conducted and the data presented in this paper
were analysed. BJ has received honoraria for being an advisor to Lundbeck.
MK has received consultancy funding from Lundbeck and Takeda, and has
received research funding from Lundbeck. MB, BR and DS were employed by
Lundbeck SAS at the time of the study concept, analysis and reporting. At
the time the study was conducted and the data presented in this paper
analysed HC was an employee of Inferential, a provider of biostatistical
consulting services working with pharmaceutical companies including
Lundbeck. YC was employed by Lundbeck SAS at time of the study concept
and analysis. LH-H is a full-time employee of H. Lundbeck A/S.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Parc Sanitari Sant Joan de Deu, Universitat de Barcelona, CIBERSAM,
C/ Doctor Antoni Pujadas 42, 08830 Sant Boi de Llobregat, Barcelona,
Spain. 2Lundbeck SAS, 37-45 Quai du Président Roosevelt, 92445
Issy-les-Moulineaux, France. 3Department of Economics, Stockholm
School of Economics, Sveavägen 65, 113 83 Stockholm, Sweden.
4Personal Social Services Research Unit, Cowdray House, London
School of Economics and Political Science, Houghton Street, London
WC2A 2AE, UK. 5Inferential, 35 rue Godot de Mauroy, 75009 Paris,
France. 6H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark. 7Present
address: Merck KGaA, Darmstadt, Germany. 8Present address: Capionis,
Bordeaux, France. 9Present address: Pierre Fabre SA, Boulogne, France.
10Present address: Janssen, Issy-les-Moulineaux, France.
Received: 15 February 2017 Accepted: 8 March 2018
References
1. National Collaborating Centre for Mental Health. Depression: The NICE
guideline on the treatment and management of depression in adults
(updated edition). 2010. https://www.ncbi.nlm.nih.gov/pubmedhealth/
PMH0016605/pdf/PubMedHealth_PMH0016605.pdf. Accessed 24 Jan 2017.
2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D,
et al. Acute and longer-term outcomes in depressed outpatients requiring
one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;
163(11):1905–17.
3. Souery D, Amsterdam J, De Montigny C, Lecrubier Y, Montgomery S,
Lipp O, et al. Treatment resistant depression: methodological overview
and operational criteria. Eur Neuropsychopharmacol. 1999;9(1–2):83–91.
4. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al.;
STAR*D study team. Evaluation of outcomes with citalopram for depression
using measurement-based care in STAR*D: implications for clinical practice.
Am J Psychiatry 2006;163(1):28–40.5. American Psychiatric Association. Practice guideline for the treatment of
patients with major depressive disorder. Third edition. 2010. http://
psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/
mdd.pdf. Accessed 24 Jan 2017.
6. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ. World
Federation of Societies of biological psychiatry (WFSBP) guidelines for
biological treatment of unipolar depressive disorders, part 1: update 2013
on the acute and continuation treatment of unipolar depressive disorders.
World J Biol Psychiatry. 2013;14(5):334–85.
7. Möller HJ, Bitter I, Bobes J, Fountoulakis K, Höschl C, Kasper S. European
Psychiatric Association. Position statement of the European Psychiatric
Association (EPA) on the value of antidepressants in the treatment of
unipolar depression. Eur Psychiatry. 2012;27(2):114–28.
8. National Institute for Health and Clinical Excellence. NICE clinical guideline
90. Depression in adults: recognition and management. 2009. https://www.
nice.org.uk/guidance/cg90/resources/depression-in-adults-recognition-and-
management-975742636741. Accessed 24 Jan 2017.
9. Rubo J, Macpherson H, Young A. Atypical antipsychotics and other
therapeutic options for treatment of resistant major depressive disorder.
Pharmaceuticals. 2010;3:3522–42.
10. Garcia-Toro M, Medina E, Galan JL, Gonzalez MA, Maurino J. Treatment
patterns in major depressive disorder after an inadequate response to first-
line antidepressant treatment. BMC Psychiatry. 2012;12:143.
11. Lamy FX, Chollet J, Clay E, Brignone M, Rive B, Saragoussi D.
Pharmacotherapeutic strategies for patients treated for depression in UK
primary care: a database analysis. Curr Med Res Opin. 2015;31(4):795–807.
12. Saragoussi D, Chollet J, Bineau S, Chalem Y, Milea D. Antidepressant
switching patterns in the treatment of major depressive disorder: a General
Practice Research Database (GPRD) study. Int J Clin Pract. 2012;66(11):1079–87.
13. Sicras-Mainar A, Maurino J, Cordero L, Blanca-Tamayo M, Navarro-Artieda R.
Assessment of pharmacological strategies for management of major depressive
disorder and their costs after an inadequate response to first-line antidepressant
treatment in primary care. Ann General Psychiatry. 2012;11(1):22.
14. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression:
a meta-analysis comparing within- versus across-class switches. Biol Psychiatry.
2008;63(7):699–704.
15. Papakostas GI. Managing partial response or nonresponse: switching,
augmentation, and combination strategies for major depressive disorder.
J Clin Psychiatry. 2009;70(Suppl 6):16–25.
16. Trivedi MH, Morris DW, Wisniewski SR, Lesser I, Nierenberg AA, Daly E, et al.
Increase in work productivity of depressed individuals with improvement in
depressive symptom severity. Am J Psychiatry. 2013;170(6):633–41.
17. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression
severity measure. J Gen Intern Med. 2001;16(9):606–13.
18. Guy W. Clinical global impressions. ECDEU assessment manual for
psychopharmacology. Rockville: National Institute of Mental Health; 1976.
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive
to change. Br J Psychiatry. 1979;134:382–9.
20. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int
Clin Psychopharmacol. 1996;11(Suppl 3):89–95.
21. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work
productivity and activity impairment instrument. Pharmacoeconomics. 1993;
4(5):353–65.
22. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight
KM, et al. The Arizona sexual experience scale (ASEX): reliability and validity.
J Sex Marital Ther. 2000;26(1):25–40.
23. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey:
construction of scales and preliminary tests of reliability and validity. Med
Care. 1996;34(3):220–33.
24. EuroQol Group. EuroQol – a new facility for the measurement of health-
related quality of life. Health Policy. 1990;16(3):199–208.
25. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK
population survey. Discussion paper 138. York: University of York; September
1995. http://www.york.ac.uk/che/pdf/DP138.pdf. Accessed 24 Jan 2017.
26. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major
depressive disorder: a meta-analysis. Curr Med Res Opin. 2009;25(1):161–75.
27. Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major
depressive disorder: a meta-analysis of head-to-head randomized clinical
trials. J Clin Pharm Ther. 2013;35(2):177–88.
28. Santaguida PL, MacQueen G, Keshavarz H, Levine M, Beyene J, Raina P.
Treatment for depression after unsatisfactory response to SSRIs. AHRQ
Haro et al. BMC Psychiatry  (2018) 18:80 Page 11 of 11publication no.12-EHC050-EF. Rockville: Agency for Healthcare Research and
Quality; 2012.
29. Simon GE, Revicki D, Heiligenstein J, Grothaus L, VonKorff M, Katon WJ, et al.
Recovery from depression, work productivity, and health care costs among
primary care patients. Gen Hosp Psychiatry. 2000;22(3):153–62.
30. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with
venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;
178:234–41.
31. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of
duloxetine and selective serotonin reuptake inhibitors: comparisons as
assessed by remission rates in patients with major depressive disorder.
J Clin Psychopharmacol. 2007;27(6):672–6.
32. Vergouwen AC, Burger H, Koerselman F, Verheij TJ. Initial rate of improvement
in relation to remission of major depressive disorder in primary care. Prim Care
Companion J Clin Psychiatry. 2007;9(5):364–6.
33. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME,
et al.; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after
failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–42.
34. Lenderking W, Samp J, Hanlon J, Hsieh R, Revicki DA, Akhras KS. Adherence,
switching and discontinuation during the 12 weeks following
antidepressant initiation in patients with depressive disorder: results of a
prospective longitudinal study. Value Health. 2013;16(7):A550.
35. Köhler S, Unger T, Hoffmann S, Mackert A, Ross B, Fydrich T. The relationship of
health-related quality of life and treatment outcome during inpatient treatment
of depression. Qual Life Res. 2015;24(3):641–9.
36. Kontodimopoulos N, Pappa E, Niakas D, Tountas Y. Validity of SF-12
summary scores in a Greek general population. Health Qual Life Outcomes.
2007;5:55.
37. Ware J, Kosinski M, Keller SK. SF-36® physical and mental health summary
scales: a user’s manual. Boston: The Health Institute; 1994.
38. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, et al.
Selecting among second-step antidepressant medication monotherapies:
predictive value of clinical, demographic, or first-step treatment features.
Arch Gen Psychiatry. 2008;65(8):870–80.
39. Schultz J, Joish V. Costs associated with changes in antidepressant
treatment in a managed care population with major depressive disorder.
Psychiatr Serv. 2009;60(12):1604–11.
40. Sheffield RE, Lo Sasso AT, Young CH, Way K. Selective serotonin reuptake
inhibitor usage patterns as risk factors for hospitalization. Admin Policy
Ment Health. 2002;30(2):121–39.
41. Beck A, Crain AL, Solberg LI, Unützer J, Glasgow RE, Maciosek MV, et al.
Severity of depression and magnitude of productivity loss. Ann Fam Med.
2011;9(4):305–11.
42. Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing
health status in primary care patients with major depressive disorder. Health
Qual Life Outcomes. 2004;2:20.
43. Elliott TE, Renier CM, Palcher JA. Chronic pain, depression, and quality of life:
correlations and predictive value of the SF-36. Pain Med. 2003;4(4):331–9.
44. Jiao J, Vincent A, Cha SS, Luedtke CA, Oh TH. Relation of age with symptom
severity and quality of life in patients with fibromyalgia. Mayo Clin Proc.
2014;89(2):199–206.
45. Novick D, Montgomery W, Kadziola Z, Moneta V, Peng X, Brugnoli R,
Haro JM. Do concomitant pain symptoms in patients with major depression
affect quality of life even when taking into account baseline depression
severity? Patient Prefer Adherence. 2013;7:463–70.
46. Soriano-Maldonado A, Amris K, Ortega FB, Segura-Jiménez V, Estévez-López
F, Álvarez-Gallardo IC, et al. Association of different levels of depressive
symptoms with symptomatology, overall disease severity, and quality of life
in women with fibromyalgia. Qual Life Res. 2015;24(12):2951–7.
47. Castillo RC, Wegener ST, Heins SE, Haythornthwaite JA, Mackenzie EJ, Bosse
MJ; LEAP study group. Longitudinal relationships between anxiety, depression,
and pain: results from a two-year cohort study of lower extremity trauma
patients. Pain. 2013;154(12):2860–6.
48. Means-Christensen AJ, Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB.
Relationships among pain, anxiety, and depression in primary care. Depress
Anxiety. 2008;25(7):593–600.
49. Fava M, Rush AJ, Alpert JE, Carmin CN, Balasubramani GK, Wisniewski SR,
et al. What clinical and symptom features and comorbid disorders characterize
outpatients with anxious major depressive disorder: a replication and extension.
Can J Psychiatr. 2006;51(13):823–35.50. Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based
prescribing for personalized medicine. Neuropsychiatr Dis Treat. 2015;11:
875–88.
51. Boyd A, Van de Velde S, Vilagut G, de Graaf R, O’Neill S, Florescu S, et al.
Gender differences in mental disorders and suicidality in Europe: results
from a large cross-sectional population-based study. J Affect Disord. 2015;
173:245–54.
52. Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M.
Factors associated with health-related quality of life among outpatients
with major depressive disorder: a STAR*D report. J Clin Psychiatry. 2006;
67(2):185–95.
53. Andresen R, Caputi P, Oades LG. Do clinical outcome measures assess
consumer-defined recovery? Psychiatry Res. 2010;177(3):309–17.
54. IsHak WW, Mirocha J, Pi S, Tobia G, Becker B, Peselow ED, Cohen RM.
Patient-reported outcomes before and after treatment of major depressive
disorder. Dialogues Clin Neurosci. 2014;16(2):171–83.
55. Slade M, Longden E. Empirical evidence about recovery and mental health.
BMC Psychiatry. 2015;15:285. https://doi.org/10.1186/s12888-015-0678-4.
56. Oliveira-Maia AJ, Mendonça C, Pessoa MJ, Camacho M, Gago J. The mental
health recovery measure can be used to assess aspects of both customer-
based and service-based recovery in the context of severe mental illness.
Front Psychol. 2016;7:1679.
57. Kovess-Masfety V, Alonso J, Brugha TS, Angermeyer MC, Haro JM, Sevilla-
Dedieu C; ESEMeD/MHEDEA 2000 investigators. Differences in lifetime use
of services for mental health problems in six European countries. Psychiatr
Serv. 2007;58(2):213–20.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
